Puma Biotechnology Inc (PBYI) stock prices updated...
 

Puma Biotechnology Inc stock price

Puma Biotechnology Inc latest news:


  • 01/23/2018 14:37:03

    Puma Biotech shares drop more than 20% as European OK of breast cancer drug unlikely

    Puma Biotechnology Inc. shares fell Tuesday after the biotech company said it will likely not get a positive result on its European marketing application for a breast cancer treatment. Puma Biotechnology shares dropped 25% to $68 after hours. The company said the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a "negative trend vote" for the drug neratinib to treat early stage HER2-positive breast cancer, meaning it will not likely get approval in a decision scheduled in February, and that additional steps would likely be needed to get a positive approval. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/23/2018 14:33:47

    BRIEF-Puma Biotechnology Says EMA's CHMP Has Communicated A Negative Trend Vote For Its Breast Cancer Treatment, ...

    Puma Biotechnology Inc(PBYI): * PUMA BIOTECHNOLOGY ANNOUNCES RESULTS OF CHMP ORAL EXPLANATION FOR NERATINIB FOR EXTENDED ADJUVANT TREATMENT OF HER2-POSITIVE EARLY STAGE BREAST CANCER.

  • 01/23/2018 14:33:33

    BRIEF-Puma Biotechnology Says EMA's CHMP Has Communicated A Negative Trend Vote For Its Breast Cancer Treatment, Neratinib

    * PUMA BIOTECHNOLOGY ANNOUNCES RESULTS OF CHMP ORAL EXPLANATION FOR NERATINIB FOR EXTENDED ADJUVANT TREATMENT OF HER2-POSITIVE EARLY STAGE BREAST CANCER

  • 01/11/2018 14:19:24

    BRIEF-Puma Biotechnology Intends To Modify Characteristics Summary In Neratinib Marketing Authorization Application

    * PUMA BIOTECHNOLOGY INC SAYS IT MET WITH COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE SCIENTIFIC ADVISORY GROUP ON ONCOLOGY

  • 12/12/2017 14:44:37

    BRIEF-Daiichi Sankyo And Puma Biotechnology To Collaborate With Major Cancer Center In HER2-Mutated Cancer

    * DAIICHI SANKYO AND PUMA BIOTECHNOLOGY ANNOUNCE RESEARCH COLLABORATION WITH MAJOR CANCER CENTER IN HER2-MUTATED CANCER Source text for Eikon: Further company coverage:

  • 12/11/2017 09:48:44

    BRIEF-Puma Biotechnology Announces Positive Outcome Of European Opposition Proceedings

    Puma Biotechnology Inc(PBYI): * PUMA BIOTECHNOLOGY ANNOUNCES POSITIVE OUTCOME OF EUROPEAN OPPOSITION PROCEEDINGS. * PUMA BIOTECHNOLOGY(PBYI) - EUROPEAN PATENT OFFICE HAS UPHELD CLAIMS IN PUMA'S LICENSED EUROPEAN PATENT, EP 2416774, WHICH WERE BEING OPPOSED BY HEXAL AG Source text for Eikon: Further company coverage:

  • More trends:

    Putnam High Income Bond FundPCF | Putnam Managed Municipal Income TrustPMM | Putnam Master Intermediate Income TrustPIM | Putnam Municipal Opportunities TrustPMO | Putnam Premier Income TrustPPT | PVH Corp.PVH | Pzena Investment Management IncPZN | Q2 HoldingsQTWO | QEP ResourcesQEP | Qihoo 360 Technology Co. Ltd.QIHU |